← All trials
NCT07311993
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 5, 2025
- Primary completion
- Feb 29, 2028
- Completion date
- Jul 31, 2029
- First posted
- Dec 31, 2025
- Last posted
- Dec 31, 2025
- Enrollment
- 60
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Cellectar, IncLead sponsor
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.